BioSpace News Archive

Growing demand for reliable early-stage diagnosis of chronic ailments is likely to add impetus to molecular diagnostics market growth over the forecast spell.

Neura, the leader in AI-powered Behavioral Intelligence, is partnering with Tripadvisor to provide the general public complete transparency regarding COVID-19 risks.

Hoag Memorial Hospital Presbyterian is building upon its personalized, science-based approach to cancer care with the launch of its Molecular Imaging and Therapy Program, led by nationally recognized expert Gary A. Ulaner, M.D., Ph.D.

Ohana Biosciences, a pioneering reproductive health company that created the world’s first sperm biology product platform, today announced the publication of foundational research conducted by Ohana scientists, unveiling a newly discovered mechanism in sperm biology that creates differences in individual human sperm cells.

Saama Technologies, Inc. (“Saama”), the #1 AI clinical analytics platform company, announced today that Ian Holmes, Ph.D., has joined its Swiss Board of Directors, effective January 1, 2021.

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced registered direct offering of 25,000,000 shares of its common stock.

Ubiquigent Limited (Ubiquigent) and the Mottram Laboratory at the University of York today announced a collaboration to investigate the inhibition of deubiquitylase (DUB) enzymes expressed by the protozoan Leishmania mexicana for the treatment of leishmaniasis

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer.

AdminaHealth CEO and Founding Member Robert Bull has been selected to be one of three solutions executives addressing insurance attendees at ASCEND’s Agency Growth & Leadership Summit, which runs from January 20-22, 2021.

Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.